Nature Communications (Jan 2021)
Human antibodies targeting a Mycobacterium transporter protein mediate protection against tuberculosis
- Avia Watson,
- Hao Li,
- Bingting Ma,
- Ronen Weiss,
- Daniele Bendayan,
- Lilach Abramovitz,
- Noam Ben-Shalom,
- Michael Mor,
- Erica Pinko,
- Michal Bar Oz,
- Zhenqi Wang,
- Fengjiao Du,
- Yu Lu,
- Jan Rybniker,
- Rony Dahan,
- Hairong Huang,
- Daniel Barkan,
- Ye Xiang,
- Babak Javid,
- Natalia T. Freund
Affiliations
- Avia Watson
- Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University
- Hao Li
- Centre for Global Health and Infectious Diseases, Collaborative Innovation Centre for the Diagnosis and Treatment of Infectious Diseases, Tsinghua University School of Medicine
- Bingting Ma
- Advanced Innovation Center for Structural Biology & Beijing Frontier Research Center for Biological Structure, Tsinghua University School of Medicine
- Ronen Weiss
- Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University
- Daniele Bendayan
- Pulmonary and Tuberculosis Department, Shmuel Harofe Hospital
- Lilach Abramovitz
- Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University
- Noam Ben-Shalom
- Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University
- Michael Mor
- Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University
- Erica Pinko
- Pulmonary and Tuberculosis Department, Shmuel Harofe Hospital
- Michal Bar Oz
- Koret School of Veterinary Medicine, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem
- Zhenqi Wang
- Centre for Global Health and Infectious Diseases, Collaborative Innovation Centre for the Diagnosis and Treatment of Infectious Diseases, Tsinghua University School of Medicine
- Fengjiao Du
- Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University
- Yu Lu
- Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University
- Jan Rybniker
- Department of Internal Medicine, Division of Infectious Diseases, University of Cologne
- Rony Dahan
- Department of Immunology, Weizmann Institute of Science
- Hairong Huang
- National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute
- Daniel Barkan
- Koret School of Veterinary Medicine, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem
- Ye Xiang
- Advanced Innovation Center for Structural Biology & Beijing Frontier Research Center for Biological Structure, Tsinghua University School of Medicine
- Babak Javid
- Centre for Global Health and Infectious Diseases, Collaborative Innovation Centre for the Diagnosis and Treatment of Infectious Diseases, Tsinghua University School of Medicine
- Natalia T. Freund
- Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University
- DOI
- https://doi.org/10.1038/s41467-021-20930-0
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 11
Abstract
Antibody responses against Mycobacteria infection have been reported, but whether and how they impact anti-bacteria immunity in the host is unclear. Here the authors characterize human anti-Mycobacteria antibodies to find them targeting a Mycobacteria transporter protein, PstS1, show distinct interaction modes in crystal structure, and mediate protection in vitro.
